These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19018327)

  • 1. Focus on ziprasidone: a review of its use in child and adolescent psychiatry.
    Elbe D; Carandang CG
    J Can Acad Child Adolesc Psychiatry; 2008 Nov; 17(4):220-9. PubMed ID: 19018327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on aripiprazole: a review of its use in child and adolescent psychiatry.
    Greenaway M; Elbe D
    J Can Acad Child Adolesc Psychiatry; 2009 Aug; 18(3):250-60. PubMed ID: 19718428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
    Toren P; Ratner S; Laor N; Weizman A
    Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials.
    Harrington CA; English C
    Pharmacotherapy; 2011 Sep; 31(9):840-9. PubMed ID: 21923584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best clinical practice with ziprasidone IM: update after 2 years of experience.
    Zimbroff DL; Allen MH; Battaglia J; Citrome L; Fishkind A; Francis A; Herr DL; Hughes D; Martel M; Preval H; Ross R
    CNS Spectr; 2005 Sep; 10(9):1-15. PubMed ID: 16247923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile.
    Stip E; Zhornitsky S; Moteshafi H; Létourneau G; Stikarovska I; Potvin S; Tourjman V
    Clin Ther; 2011 Dec; 33(12):1853-67. PubMed ID: 22133697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    CNS Drugs; 2002; 16(9):645-52. PubMed ID: 12153335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overdoses and ingestions of second-generation antipsychotics in children and adolescents.
    Antia SX; Sholevar EH; Baron DA
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):970-85. PubMed ID: 16379518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of atypical antipsychotics in the treatment of autistic disorder.
    Stachnik JM; Nunn-Thompson C
    Ann Pharmacother; 2007 Apr; 41(4):626-34. PubMed ID: 17389666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety evaluation of ziprasidone.
    Citrome L
    Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment options in bipolar disorder in adolescents: focus on ziprasidone.
    Khan AA; Strawn JR; Croarkin PE
    Adolesc Health Med Ther; 2010; 1():137-43. PubMed ID: 24600269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective observational multi-poison center study of ziprasidone exposures.
    Klein-Schwartz W; Lofton AL; Benson BE; Spiller HA; Crouch BI
    Clin Toxicol (Phila); 2007; 45(7):782-6. PubMed ID: 17926152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.
    Greenberg WM; Citrome L
    CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ziprasidone for schizophrenia and severe mental illness.
    Bagnall A; Lewis RA; Leitner ML
    Cochrane Database Syst Rev; 2000; (4):CD001945. PubMed ID: 11034737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agitation and/or aggression after traumatic brain injury in the pediatric population treated with ziprasidone. Clinical article.
    Scott LK; Green R; McCarthy PJ; Conrad SA
    J Neurosurg Pediatr; 2009 Jun; 3(6):484-7. PubMed ID: 19485732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturalistic study of intramuscular ziprasidone versus conventional agents in agitated elderly patients: retrospective findings from a psychiatric emergency service.
    Kohen I; Preval H; Southard R; Francis A
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):240-5. PubMed ID: 16503319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.